Related Experiment Videos
Refractory polyarteritis nodosa successfully treated with infliximab.
Jamal Al-Bishri1, Nicole le Riche, Janet E Pope
1Division of Rheumatology, Department of Medicine, University of Western Ontario, London, Ontario, Canada.
The Journal of Rheumatology
|July 5, 2005
Summary
This case study shows that infliximab effectively treated a severe case of polyarteritis nodosa (PAN) that did not respond to other immunosuppressants. Infliximab offers a potential new treatment for refractory PAN.
Area of Science:
- Rheumatology
- Immunology
- Vascular Medicine
Background:
- Polyarteritis nodosa (PAN) is a severe systemic vasculitis.
- Visceral organ involvement in PAN often indicates a poor prognosis.
- Treatment resistance to conventional immunosuppressants poses a significant clinical challenge.
Observation:
- A patient with severe, multi-organ PAN unresponsive to various immunosuppressive therapies was identified.
- The patient's condition included significant visceral involvement.
- Standard treatment protocols failed to induce remission or control disease activity.
Findings:
- Infliximab, a biologic TNF-alpha inhibitor, was administered to the refractory PAN patient.
- The patient exhibited a remarkable and positive response to infliximab treatment.
- Sustained remission and significant improvement in visceral involvement were observed.
Implications:
- Infliximab demonstrates potential efficacy as an alternative therapeutic option for severe PAN.
- This finding is particularly relevant for patients with PAN refractory to established treatments.
- Further research into infliximab's role in managing refractory vasculitis is warranted.